Now showing items 1-6 of 6

    • ATR Is a Therapeutic Target in Synovial Sarcoma. 

      Jones, SE; Fleuren, EDG; Frankum, J; Konde, A; Williamson, CT; Krastev, DB; Pemberton, HN; Campbell, J; Gulati, A; Elliott, R; Menon, M; Selfe, JL; Brough, R; Pettitt, SJ; Niedzwiedz, W; van der Graaf, WTA; Shipley, J; Ashworth, A; Lord, CJ (2017-12-15)
      Synovial sarcoma (SS) is an aggressive soft-tissue malignancy characterized by expression of SS18-SSX fusions, where treatment options are limited. To identify therapeutically actionable genetic dependencies in SS, we ...
    • Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness. 

      Holme, H; Gulati, A; Brough, R; Fleuren, EDG; Bajrami, I; Campbell, J; Chong, IY; Costa-Cabral, S; Elliott, R; Fenton, T; Frankum, J; Jones, SE; Menon, M; Miller, R; Pemberton, HN; Postel-Vinay, S; Rafiq, R; Selfe, JL; von Kriegsheim, A; Munoz, AG; Rodriguez, J; Shipley, J; van der Graaf, WTA; Williamson, CT; Ryan, CJ; Pettitt, S; Ashworth, A; Strauss, SJ; Lord, CJ (2018-07-13)
      Osteosarcoma (OS) is an aggressive sarcoma, where novel treatment approaches are required. Genomic studies suggest that a subset of OS, including OS tumour cell lines (TCLs), exhibit genomic loss of heterozygosity (LOH) ...
    • Clinical outcomes of adolescents and young adults with advanced solid tumours participating in phase I trials. 

      Sundar, R; McVeigh, T; Dolling, D; Petruckevitch, A; Diamantis, N; Ang, JE; Chenard-Poiriér, M; Collins, D; Lim, J; Ameratunga, M; Khan, K; Kaye, SB; Banerji, U; Lopez, J; George, AJ; de Bono, JS; van der Graaf, WT (2018-09)
      BACKGROUND: Adolescent and young adult (AYA) patients with advanced solid tumours are often considered for phase I clinical trials with novel agents. The outcome of AYAs in these trials have not been described before. AIM: ...
    • Expression and clinical association of programmed cell death-1, programmed death-ligand-1 and CD8+ lymphocytes in primary sarcomas is subtype dependent. 

      van Erp, AEM; Versleijen-Jonkers, YMH; Hillebrandt-Roeffen, MHS; van Houdt, L; Gorris, MAJ; van Dam, LS; Mentzel, T; Weidema, ME; Savci-Heijink, CD; Desar, IME; Merks, HHM; van Noesel, MM; Shipley, J; van der Graaf, WTA; Flucke, UE; Meyer-Wentrup, FAG (2017-07-07)
      In order to explore the potential of immune checkpoint blockade in sarcoma, we investigated expression and clinical relevance of programmed cell death-1 (PD-1), programmed death ligand-1 (PD-L1) and CD8 in tumors of 208 ...
    • The role of genomic profiling in adolescents and young adults (AYAs) with advanced cancer participating in phase I clinical trials. 

      McVeigh, TP; Sundar, R; Diamantis, N; Kaye, SB; Banerji, U; Lopez, JS; de Bono, J; van der Graaf, WTA; George, AJ (2018-05)
      INTRODUCTION: Adolescents and young adults (AYAs) diagnosed with cancer between ages 15-39 years may harbour germline variants associated with cancer predisposition. Such variants represent putative therapeutic targets, ...
    • A study of motivations and expectations of patients seen in phase 1 oncology clinics. 

      Dolly, SO; Kalaitzaki, E; Puglisi, M; Stimpson, S; Hanwell, J; Fandos, SS; Stapleton, S; Ansari, T; Peckitt, C; Kaye, S; Lopez, J; Yap, TA; van der Graaf, W; de Bono, J; Banerji, U (2016-09-26)
      To better inform clinical practice, this study was aimed at capturing patients' motivations for enrolling in phase 1 trials and at quantifying their expectations of the benefits, risks, and commitment associated with ...